Algeta ASA (ALGETA.OL)

ALGETA.OL

About

Algeta ASA is a Norway-based biotechnology company engaged in the development of targeted cancer therapies based on its alpha-pharmaceutical platform. The Company’s principal product is Alpharadin for the treatment of bone metastases resulting from castration-resistant prostate cancer. The Company’s pipeline also includes... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.42
Market Cap (Mil.):	kr9,345.26
Shares Outstanding (Mil.):	42.57
Dividend:	--
Yield (%):	--

Financials

	ALGETA.OL	Industry	Sector
P/E (TTM):	43.90	54.65	35.85
EPS (TTM):	5.01	--	--
ROI:	43.01	0.83	18.76
ROE:	45.47	1.79	19.57

Latest News about ALGETA.OL

Bayer, Algeta win FDA approval for prostate cancer drug

FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.

15 May 2013

» More ALGETA.OL News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Algeta ASA (ALGETA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
ALGETA - FDA GO FOR XOFIGO Provider: Edison Investment Research	$10.00 Buy
Algeta ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.